Company profile
Contineum Therapeutics, Inc.
NASDAQ:CTNMBiotechnology: Pharmaceutical Preparations
Clinical trials (7)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06683612 | phase1 | completed | 2024-12-09 | 2025-06-04 | Contineum Therapeutics | PET Study of PIPE-791 in Healthy Volunteers and Volunteers With PrMS and IPF |
| NCT04941781 | phase1 | completed | 2021-09-01 | 2021-11-10 | Contineum Therapeutics | PET Study to Determine the Relationship Between Plasma Concentrations and Muscarinic Type 1 Receptor (M1AChR) Occupancy of PIPE-307 in Healthy Volunteers |
| NCT04725175 | phase1 | completed | 2021-02-26 | 2021-09-01 | Contineum Therapeutics | Phase I Study Evaluating Safety and Tolerability of Escalating Single and Multiple Doses of of PIPE-307 and Food Effect in Healthy Volunteers |
| NCT04462198 | phase1_2 | completed | 2020-10-15 | 2021-06-17 | Contineum Therapeutics | Phase I/IIa Study Evaluating Safety and Efficacy of an Intratympanic Dose of PIPE-505 in Subjects With Hearing Loss |
| NCT05983939 | phase1 | completed | 2023-06-26 | 2024-02-01 | Contineum Therapeutics | Study Evaluating Safety and Tolerability of Escalating Single and Multiple Doses of PIPE-791 and Food Effect in Healthy Volunteers |
FDA applications (0)
No records yet.